N/A N=366 Undiagnosed Hepatitis C Infection in an Urban Hospital
Hepatitis C
Primary: Point Prevalence of Hepatitis C Infection — 9 percentage of total subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=15 Hepatitis C Virus(HCV) Heart and Lung Study
Hepatitis C, Chronic · Heart Failure · Pulmonary Disease, Chronic Obstructive
Primary: Number of Subjects Who Completed 24 Weeks of Therapy — 0; 1 Participants
Phase 1 N=5 Viral Kinetics in HCV Clearance in Subjects With Hemophilia
Chronic Hepatitis C · Hemophilia
Primary: Number of Participants With Sustained Virological Response at Week 12 (SVR12) — 2; 2 participants
Phase 2 N=55 First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV
Hepatitis B
Primary: The Incidence of Participants With Treatment-Emergent Adverse Events (TEAEs) and ≥Grade 3 Study Vaccine-related Adverse Events Following Study Vaccination — 1; 1; 2; 1…
Phase 1 N=113 Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection
Chronic Hepatitis B
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 5; 4; 5; 4 Participants
N/A N=795 Association of Hepatitis C Virus With Breast Cancer
Breast Cancer · Hepatitis C
Primary: Prevalence of HCV Seropositivity in Breast Cancer Patients. — 88; 15; 317; 130 Participants — p=0.0027
N/A N=176 Hepatitis C-Video vs. Brochure Education Delivery
Hepatitis C
Primary: Improvement in Scores on HCV Knowledge Questionnaire — 18.45; 19; 20.3; 21.75 Improvement in scores
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
Phase 4 N=371 Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
HIV Infection · Hepatitis B
Primary: Sero-response to Hepatitis B Surface Antigen — 60; 73.2; 75.4 percentage of participants who resonded — p=0.0440
Phase 4 N=21 Treatment of Acute Hepatitis C Virus in HIV Co-Infection
Hepatitis C · Human Immunodeficiency Virus · HIV Infections
Primary: Sustained Virologic Response (SVR) — 62 percentage of participants
Phase 1 N=17 MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)
Hepatitis C
Primary: Number of Participants With Vaccine-related Clinical (Systemic and Injection-site), and Laboratory Adverse Events (AE) — 5; 1; 3; 1 Participants
N/A N=149 The Relationship Between Vitamin D and Hepatitis B Virus Replication
Vitamin D and Hepatitis B Virus
Primary: The Dynamic Change of HBV DNA — 3.15; 3.14 IU/mL
Phase 4 N=28 Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)
Anti-Hepatitis A Antibody Levels in Heathy Subjects
Primary: Percentage of Subjects Maintaining Protective Anti- HAV Antibody Levels — 26 Participants
N/A N=743 Prevalence of HBV in Pregnant Women Attending Antenatal Care in Tanzania
Hepatitis B
Primary: HBsAG Prevalence — 22 Participants
Phase 2 N=548 Staged Phase I/II Hepatitis C Prophylactic Vaccine
Hepatitis C
Primary: Number of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 Months — 14; 14 Participants — p=0.317
N/A N=145 The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)
Carcinoma, Hepatocellular · Chronic Hepatitis B
Primary: 1,3,5 Year-Disease Free Survival (or Recurrence Free Survival) — 11; 13; 25; 34 participants
Phase 2 N=19 Herpes Simplex Type 1 Suppression in Hepatitis C
Chronic Hepatitis C Infection
Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05
N/A N=134 Hepatitis C Self-Management
Hepatitis C · Chronic Disease
Primary: Quality of Well-being Scale - Self-Administered (QWB-SA) — .534; .501; .600; .504 units on a scale
Phase 2 N=84 Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Chronic Hepatitis B
Primary: Number of Subjects With Adverse Events as Assessed by CTCAE v5.0 — 9; 13; 3; 16 Participants
N/A N=382 Chronic HBV Management for Asian American
Hepatitis B, Chronic
Primary: Adherence to Recommended HBV Monitoring: Doctor's Visits — 159; 100; 170; 147 Participants
N/A N=10 Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers
Hepatitis B
Primary: Number of Differentially Expressed Genes at p < 0.05 (Without Multiple Testing Correction). — 138; 138; 102; 81 number of genes at p<0.05
Phase 2 N=82 Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B
Chronic Hepatitis B
Primary: Incidence of Adverse Events (AEs) — 4; 3; 4; 5 Participants
Phase 4 N=25 HCV Positive Heart Donors
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
Phase 4 N=475 A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )
Hepatitis E
Primary: Number of Participants Whose Anti-HEV Antibody Seroconverted at One Month After The Third Dose — 188; 196 Participants
Phase 1 N=31 Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
Chronic Hepatitis C Infection
Primary: Effect of HSV-2 Suppression on HCV Viral Load. — .18; .03 log(IU/mL)
Phase 2 N=72 Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
Chronic Hepatitis C
Primary: Number of Participants With Sustained Virologic Response — 70 Participants
Phase 2 N=12 A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B
Hepatitis B
Primary: Percentage of Participants Achieving Serum Hepatitis B Virus Surface Antigen (HBsAg) Level Less Than (<) Lower Limit of Quantitation (LLOQ) — 25 Percentage of participants
Phase 2 N=41 Lamivudine and Adefovir to Treat Chronic Hepatitis B
HBV (Hepatitis B Virus) · Hepatitis B · Hepatitis
Primary: Maintained Combined Response (Virological, Biochemical and Histological Response). — 15; 6; 7; 13 participants — p=0.0294
Phase 2 N=105 Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil
Chronic Hepatitis B
Primary: Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48 — 75.5; 69.2 percentage of participants — p=.544
Phase 2 N=36 Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients
Hepatitis C · HIV Infections
Primary: Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response — 8 participants with post treatment svr